Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neda Stjepanovic

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Breast Cancer Research and Treatment|January 10, 2021
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriersNeda Stjepanovic, Jan Lubinski, Pal Moller, et al.
Journal of Medical Genetics|November 26, 2018
Screening of <i>BRCA1/2</i> deep intronic regions by targeted gene sequencing identifies the first germline <i>BRCA1</i> variant causing pseudoexon activation in a patient with breast/ovarian cancerGemma Montalban, Sandra Bonache, Alejandro Moles-Fernández, et al.
International Journal of Cancer|March 31, 2019
Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panelsLídia Feliubadaló, Adrià López-Fernández, Marta Pineda, et al.
Future Oncology (London, England)|January 6, 2026
A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study designNaureen Starling, Elena Elez, John H Strickler, et al.
Breast Cancer Research and Treatment|December 16, 2018
Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>TLaura Duran-Lozano, Gemma Montalban, Sandra Bonache, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2020
Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reductionNeda Stjepanovic, Guillermo Villacampa, Kevin T Nead, et al.
JTO Clinical and Research Reports|October 13, 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLCSun Min Lim, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto, et al.
Nature Communications|November 11, 2023
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trialSun Min Lim, Solange Peters, Ana Laura Ortega Granados, et al.
BMC Medical Genomics|August 11, 2018
Additional germline findings from a tumor profiling programNeda Stjepanovic, Tracy L Stockley, Philippe L Bedard, et al.
Frontiers in Genetics|September 21, 2018
Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?Alejandro Moles-Fernández, Laura Duran-Lozano, Gemma Montalban, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Breast Cancer Research and Treatment|January 10, 2021
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriersNeda Stjepanovic, Jan Lubinski, Pal Moller, et al.
Journal of Medical Genetics|November 26, 2018
Screening of <i>BRCA1/2</i> deep intronic regions by targeted gene sequencing identifies the first germline <i>BRCA1</i> variant causing pseudoexon activation in a patient with breast/ovarian cancerGemma Montalban, Sandra Bonache, Alejandro Moles-Fernández, et al.
International Journal of Cancer|March 31, 2019
Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panelsLídia Feliubadaló, Adrià López-Fernández, Marta Pineda, et al.
Future Oncology (London, England)|January 6, 2026
A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study designNaureen Starling, Elena Elez, John H Strickler, et al.
Breast Cancer Research and Treatment|December 16, 2018
Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>TLaura Duran-Lozano, Gemma Montalban, Sandra Bonache, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2020
Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reductionNeda Stjepanovic, Guillermo Villacampa, Kevin T Nead, et al.
JTO Clinical and Research Reports|October 13, 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLCSun Min Lim, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto, et al.
Nature Communications|November 11, 2023
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trialSun Min Lim, Solange Peters, Ana Laura Ortega Granados, et al.
BMC Medical Genomics|August 11, 2018
Additional germline findings from a tumor profiling programNeda Stjepanovic, Tracy L Stockley, Philippe L Bedard, et al.
Frontiers in Genetics|September 21, 2018
Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?Alejandro Moles-Fernández, Laura Duran-Lozano, Gemma Montalban, et al.
Pageof 3